Lista de obras - Walter J. Storkus - Dominio Público Uruguay

A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

artículo científico publicado en 2007

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

artículo científico publicado en 2010

Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.

artículo científico publicado en 2006

Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.

artículo científico publicado en 2006

Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes

artículo científico publicado en 1996

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer

artículo científico publicado en 2018

CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth.

artículo científico publicado en 2008

Chronic inflammation and immunologic-based constraints in malignant disease ⬇️

artículo científico publicado el 1 de octubre de 2011

Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen

artículo científico publicado en 1999

Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

artículo científico publicado en 2012

Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.

artículo científico publicado en 2006

Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.

artículo científico publicado en 2012

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

artículo científico publicado en 2012

Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses.

artículo científico publicado en 2002

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.

artículo científico publicado en 2009

Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials.

artículo científico publicado en 1996

DLK1: A Novel Target for Immunotherapeutic Remodeling of the Tumor Blood Vasculature ⬇️

artículo científico publicado el 30 de julio de 2013

DNA immunization targeting the skin: molecular control of adaptive immunity

artículo científico publicado en 1998

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

artículo científico publicado en 2014

Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines

scientific article published on 01 August 2004

Direct transfection and activation of human cutaneous dendritic cells

artículo científico publicado en 2001

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.

artículo científico publicado en 2004

Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine

artículo científico publicado en 2008

Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma

artículo científico publicado en 2020

EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells

scientific article published on 27 February 2007

EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients

artículo científico publicado en 2005

Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

artículo científico publicado en 2009

Effect of renal cell carcinomas on the development of type 1 T-cell responses

artículo científico publicado en 2004

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells

artículo científico publicado en 2003

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines

artículo científico publicado en 2005

Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.

artículo científico publicado en 2003

Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells

artículo científico publicado en 2013

FLT3 ligand induces the generation of functionally active dendritic cells in mice

artículo científico publicado en 1997

Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2.

artículo científico publicado en 1994

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

artículo científico publicado en 2008

Gene-based strategies for the immunotherapy of cancer ⬇️

artículo científico publicado el 1 de julio de 1997

Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes

artículo científico publicado en 2010

Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivo ⬇️

artículo científico publicado el 1 de octubre de 1997

Giving DNA vaccines a helping hand

artículo científico publicado en 1998

Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

artículo científico publicado en 2009

Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes

article

Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin

artículo científico publicado en 1996

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro.

artículo científico publicado en 2005

IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo

artículo científico publicado en 1996

IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro

article

Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

artículo científico publicado en 2006

Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

artículo científico publicado en 1999

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

artículo científico publicado en 2002

Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines

artículo científico publicado en 2007

Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity

artículo científico publicado en 2007

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

artículo científico publicado en 2008

Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.

artículo científico publicado en 1996

Interleukin‐12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long‐term Antitumor Immunity in Syngeneic C3H Mice ⬇️

artículo científico publicado el 1 de febrero de 1998

Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment.

artículo científico publicado en 2010

Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens ⬇️

artículo científico publicado el 28 de diciembre de 2010

JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.

artículo científico publicado en 2010

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

artículo científico publicado en 2003

Melanoma vaccines: in search of a clinical paradigm

scientific article published on 01 June 2007

Murine models of cancer cytokine gene therapy using interleukin-12.

artículo científico publicado en 1996

Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape ⬇️

artículo científico publicado el 1 de enero de 2012

Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12

artículo científico publicado en 2013

Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation.

artículo científico publicado en 2005

Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro

scientific article published on 01 January 2007

Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors

scientific article published on 01 July 2007

Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model

artículo científico publicado en 2002

Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells

artículo científico publicado en 2001

Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.

artículo científico publicado en 2007

Shock block for improved immunotherapy

artículo científico publicado en 2012

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors

artículo científico publicado en 2021

Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination ⬇️

artículo científico publicado el 25 de mayo de 2011

Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32 ⬇️

artículo científico publicado el 15 de julio de 2011

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

artículo científico publicado en 2007

Tumor-Derived Vascular Pericytes Anergize Th Cells ⬇️

artículo científico publicado el 19 de junio de 2013

Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis.

artículo científico

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

artículo científico publicado en 2004

Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice

artículo científico publicado en 2012

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

artículo científico publicado en 2004

gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells ⬇️

artículo científico publicado el 30 de noviembre de 2001

Lista de obras de Walter J. Storkus

A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6.

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation.

Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.

Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer

CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth.

Chronic inflammation and immunologic-based constraints in malignant disease ⬇️

Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen

Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.

Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses.

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.

Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials.

DLK1: A Novel Target for Immunotherapeutic Remodeling of the Tumor Blood Vasculature ⬇️

DNA immunization targeting the skin: molecular control of adaptive immunity

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines

Direct transfection and activation of human cutaneous dendritic cells

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.

Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine

Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma

EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells

EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients

Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

Effect of renal cell carcinomas on the development of type 1 T-cell responses

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines

Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.

Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells

FLT3 ligand induces the generation of functionally active dendritic cells in mice

Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2.

Focus on FOCIS: interleukin 2 treatment associated autoimmunity.

Gene-based strategies for the immunotherapy of cancer ⬇️

Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes

Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivo ⬇️

Giving DNA vaccines a helping hand

Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes

Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin

Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro.

IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo

IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro

Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines

Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.

Interleukin‐12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long‐term Antitumor Immunity in Syngeneic C3H Mice ⬇️

Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment.

Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens ⬇️

JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Melanoma vaccines: in search of a clinical paradigm

Murine models of cancer cytokine gene therapy using interleukin-12.

Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape ⬇️

Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12

Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation.

Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro

Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors

Progenipoietin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model

Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells

Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.

Shock block for improved immunotherapy

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors

Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination ⬇️

Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32 ⬇️

Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

Tumor-Derived Vascular Pericytes Anergize Th Cells ⬇️

Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis.

Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells ⬇️